REVOLUTION Medicines (RVMD)

Executive Summary

Revolution Medicines is a precision oncology company pioneering the tri-complex inhibitor platform to target historically undruggable RAS oncoproteins. With a market capitalization of $18.47 billion, the company has advanced a robust pipeline of RAS(ON) inhibitors into late-stage clinical development. Lead asset RMC-6236, a RAS(ON) multi-selective inhibitor, is in a Phase 3 trial (RASolute 302) for first-line pancreatic ductal adenocarcinoma (PDAC), while daraxonrasib (RMC-6236's G12C-selective counterpart) is being evaluated in Phase 3 studies for PDAC and non-small cell lung cancer (NSCLC). Additionally, RMC-9805 (a G12D-selective inhibitor) and RMC-6291 (a G12C inhibitor) are progressing through early-phase trials. The company's platform has generated significant interest due to its potential to address a broad range of RAS-mutant cancers, which represent a large unmet medical need. Revolution Medicines is well-capitalized to execute its clinical plan, with multiple data readouts expected over the next 12-18 months that could confirm the transformative potential of its approach and support regulatory filings.

Upcoming Catalysts (preview)

• Q4 2026RMC-6236 Phase 3 RASolute 302 interim overall survival data in first-line pancreatic ductal adenocarcinoma65% success
• Q1 2027Daraxonrasib Phase 3 RASolute 301 interim overall survival data in pancreatic ductal adenocarcinoma60% success
• Q3 2026RMC-9805 Phase 1/2 dose escalation and expansion data in RAS G12D-mutant solid tumors40% success